1. 1306TiPILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. (23rd October 2018) Authors: Ascierto, P A; Arenberger, P; Atkinson, V G; Hansson, J; Kapiteijn, E; Loquai, C; Negrier, S; Shaw, H M; Tarhini, A; Walker, J; Geib, J; Rahimian, S; Swann, S; Diab, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗